Cargando…

Evaluation of the EDI enzyme linked immunosorbent assays for the detection of SARS-CoV-2 IgM and IgG antibodies in human plasma

BACKGROUND: Besides SARS-CoV-2 RT-PCR testing, serological testing is emerging as additional option in COVID-19 diagnostics. Aim of this study was to evaluate novel immunoassays for detection of SARS-CoV-2 antibodies in human plasma. METHODS: Using EDI(TM) Novel Coronavirus COVID-19 Enzyme Linked Im...

Descripción completa

Detalles Bibliográficos
Autores principales: Bundschuh, Christian, Egger, Margot, Wiesinger, Kurt, Gabriel, Christian, Clodi, Martin, Mueller, Thomas, Dieplinger, Benjamin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7278646/
https://www.ncbi.nlm.nih.gov/pubmed/32526218
http://dx.doi.org/10.1016/j.cca.2020.05.047
_version_ 1783543379198476288
author Bundschuh, Christian
Egger, Margot
Wiesinger, Kurt
Gabriel, Christian
Clodi, Martin
Mueller, Thomas
Dieplinger, Benjamin
author_facet Bundschuh, Christian
Egger, Margot
Wiesinger, Kurt
Gabriel, Christian
Clodi, Martin
Mueller, Thomas
Dieplinger, Benjamin
author_sort Bundschuh, Christian
collection PubMed
description BACKGROUND: Besides SARS-CoV-2 RT-PCR testing, serological testing is emerging as additional option in COVID-19 diagnostics. Aim of this study was to evaluate novel immunoassays for detection of SARS-CoV-2 antibodies in human plasma. METHODS: Using EDI(TM) Novel Coronavirus COVID-19 Enzyme Linked Immunosorbent Assays (ELISAs), we measured SARS-CoV-2 IgM and IgG antibodies in 64 SARS-CoV-2 RT-PCR confirmed COVID-19 patients with serial blood samples (n = 104) collected at different time points from symptom onset. Blood samples from 200 healthy blood donors and 256 intensive care unit (ICU) patients collected before the COVID-19 outbreak were also used. RESULTS: The positivity rates in the COVID-19 patients were 5.9% for IgM and 2.9% for IgG ≤ 5 days after symptom onset; Between day 5 and day 10 the positivity rates were 37.1% for IgM and 37.1% for IgG and rose to 76.4% for IgM and 82.4% for IgG after > 10–15 days. After 15–22 days the “true” positivity rates were 94.4% for IgM and 100% for IgG. The “false” positivity rates were 0.5% for IgM and 1.0% for IgG in the healthy blood donors, 1.6% for IgM and 1.2% for IgG in ICU patients. CONCLUSIONS: This study shows high “true” vs. low “false” positivity rates for the EDI(TM) SARS-CoV-2 IgM and IgG ELISAs.
format Online
Article
Text
id pubmed-7278646
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-72786462020-06-09 Evaluation of the EDI enzyme linked immunosorbent assays for the detection of SARS-CoV-2 IgM and IgG antibodies in human plasma Bundschuh, Christian Egger, Margot Wiesinger, Kurt Gabriel, Christian Clodi, Martin Mueller, Thomas Dieplinger, Benjamin Clin Chim Acta Article BACKGROUND: Besides SARS-CoV-2 RT-PCR testing, serological testing is emerging as additional option in COVID-19 diagnostics. Aim of this study was to evaluate novel immunoassays for detection of SARS-CoV-2 antibodies in human plasma. METHODS: Using EDI(TM) Novel Coronavirus COVID-19 Enzyme Linked Immunosorbent Assays (ELISAs), we measured SARS-CoV-2 IgM and IgG antibodies in 64 SARS-CoV-2 RT-PCR confirmed COVID-19 patients with serial blood samples (n = 104) collected at different time points from symptom onset. Blood samples from 200 healthy blood donors and 256 intensive care unit (ICU) patients collected before the COVID-19 outbreak were also used. RESULTS: The positivity rates in the COVID-19 patients were 5.9% for IgM and 2.9% for IgG ≤ 5 days after symptom onset; Between day 5 and day 10 the positivity rates were 37.1% for IgM and 37.1% for IgG and rose to 76.4% for IgM and 82.4% for IgG after > 10–15 days. After 15–22 days the “true” positivity rates were 94.4% for IgM and 100% for IgG. The “false” positivity rates were 0.5% for IgM and 1.0% for IgG in the healthy blood donors, 1.6% for IgM and 1.2% for IgG in ICU patients. CONCLUSIONS: This study shows high “true” vs. low “false” positivity rates for the EDI(TM) SARS-CoV-2 IgM and IgG ELISAs. Elsevier B.V. 2020-10 2020-06-08 /pmc/articles/PMC7278646/ /pubmed/32526218 http://dx.doi.org/10.1016/j.cca.2020.05.047 Text en © 2020 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Bundschuh, Christian
Egger, Margot
Wiesinger, Kurt
Gabriel, Christian
Clodi, Martin
Mueller, Thomas
Dieplinger, Benjamin
Evaluation of the EDI enzyme linked immunosorbent assays for the detection of SARS-CoV-2 IgM and IgG antibodies in human plasma
title Evaluation of the EDI enzyme linked immunosorbent assays for the detection of SARS-CoV-2 IgM and IgG antibodies in human plasma
title_full Evaluation of the EDI enzyme linked immunosorbent assays for the detection of SARS-CoV-2 IgM and IgG antibodies in human plasma
title_fullStr Evaluation of the EDI enzyme linked immunosorbent assays for the detection of SARS-CoV-2 IgM and IgG antibodies in human plasma
title_full_unstemmed Evaluation of the EDI enzyme linked immunosorbent assays for the detection of SARS-CoV-2 IgM and IgG antibodies in human plasma
title_short Evaluation of the EDI enzyme linked immunosorbent assays for the detection of SARS-CoV-2 IgM and IgG antibodies in human plasma
title_sort evaluation of the edi enzyme linked immunosorbent assays for the detection of sars-cov-2 igm and igg antibodies in human plasma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7278646/
https://www.ncbi.nlm.nih.gov/pubmed/32526218
http://dx.doi.org/10.1016/j.cca.2020.05.047
work_keys_str_mv AT bundschuhchristian evaluationoftheedienzymelinkedimmunosorbentassaysforthedetectionofsarscov2igmandiggantibodiesinhumanplasma
AT eggermargot evaluationoftheedienzymelinkedimmunosorbentassaysforthedetectionofsarscov2igmandiggantibodiesinhumanplasma
AT wiesingerkurt evaluationoftheedienzymelinkedimmunosorbentassaysforthedetectionofsarscov2igmandiggantibodiesinhumanplasma
AT gabrielchristian evaluationoftheedienzymelinkedimmunosorbentassaysforthedetectionofsarscov2igmandiggantibodiesinhumanplasma
AT clodimartin evaluationoftheedienzymelinkedimmunosorbentassaysforthedetectionofsarscov2igmandiggantibodiesinhumanplasma
AT muellerthomas evaluationoftheedienzymelinkedimmunosorbentassaysforthedetectionofsarscov2igmandiggantibodiesinhumanplasma
AT dieplingerbenjamin evaluationoftheedienzymelinkedimmunosorbentassaysforthedetectionofsarscov2igmandiggantibodiesinhumanplasma